These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23254420)

  • 21. Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages.
    Sorrentino F; Gonzalez del Rio R; Zheng X; Presa Matilla J; Torres Gomez P; Martinez Hoyos M; Perez Herran ME; Mendoza Losana A; Av-Gay Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):640-5. PubMed ID: 26503663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.
    de Carvalho LP; Lin G; Jiang X; Nathan C
    J Med Chem; 2009 Oct; 52(19):5789-92. PubMed ID: 19736929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metal-based antimicrobial strategies against intramacrophage Mycobacterium tuberculosis.
    Coelho TS; Halicki PCB; Silva L; de Menezes Vicenti JR; Gonçalves BL; Almeida da Silva PE; Ramos DF
    Lett Appl Microbiol; 2020 Aug; 71(2):146-153. PubMed ID: 32286695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model.
    Grant SS; Kawate T; Nag PP; Silvis MR; Gordon K; Stanley SA; Kazyanskaya E; Nietupski R; Golas A; Fitzgerald M; Cho S; Franzblau SG; Hung DT
    ACS Chem Biol; 2013 Oct; 8(10):2224-34. PubMed ID: 23898841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
    Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
    J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.
    Ballell L; Bates RH; Young RJ; Alvarez-Gomez D; Alvarez-Ruiz E; Barroso V; Blanco D; Crespo B; Escribano J; González R; Lozano S; Huss S; Santos-Villarejo A; Martín-Plaza JJ; Mendoza A; Rebollo-Lopez MJ; Remuiñan-Blanco M; Lavandera JL; Pérez-Herran E; Gamo-Benito FJ; García-Bustos JF; Barros D; Castro JP; Cammack N
    ChemMedChem; 2013 Feb; 8(2):313-21. PubMed ID: 23307663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis.
    Mak PA; Rao SP; Ping Tan M; Lin X; Chyba J; Tay J; Ng SH; Tan BH; Cherian J; Duraiswamy J; Bifani P; Lim V; Lee BH; Ling Ma N; Beer D; Thayalan P; Kuhen K; Chatterjee A; Supek F; Glynne R; Zheng J; Boshoff HI; Barry CE; Dick T; Pethe K; Camacho LR
    ACS Chem Biol; 2012 Jul; 7(7):1190-7. PubMed ID: 22500615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating
    Lopez Quezada L; Li K; McDonald SL; Nguyen Q; Perkowski AJ; Pharr CW; Gold B; Roberts J; McAulay K; Saito K; Somersan Karakaya S; Javidnia PE; Porras de Francisco E; Amieva MM; Dı Az SP; Mendoza Losana A; Zimmerman M; Liang HH; Zhang J; Dartois V; Sans S; Lagrange S; Goullieux L; Roubert C; Nathan C; Aubé J
    ACS Infect Dis; 2019 Aug; 5(8):1433-1445. PubMed ID: 31184461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microplate Alamar Blue Assay (MABA) and Low Oxygen Recovery Assay (LORA) for Mycobacterium tuberculosis.
    Cho S; Lee HS; Franzblau S
    Methods Mol Biol; 2015; 1285():281-92. PubMed ID: 25779323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
    Dkhar HK; Gopalsamy A; Loharch S; Kaur A; Bhutani I; Saminathan K; Bhagyaraj E; Chandra V; Swaminathan K; Agrawal P; Parkesh R; Gupta P
    J Biol Chem; 2015 Jan; 290(1):76-89. PubMed ID: 25384979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG.
    Mori G; Chiarelli LR; Esposito M; Makarov V; Bellinzoni M; Hartkoorn RC; Degiacomi G; Boldrin F; Ekins S; de Jesus Lopes Ribeiro AL; Marino LB; Centárová I; Svetlíková Z; Blaško J; Kazakova E; Lepioshkin A; Barilone N; Zanoni G; Porta A; Fondi M; Fani R; Baulard AR; Mikušová K; Alzari PM; Manganelli R; de Carvalho LP; Riccardi G; Cole ST; Pasca MR
    Chem Biol; 2015 Jul; 22(7):917-27. PubMed ID: 26097035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053.
    Chiarelli LR; Salina EG; Mori G; Azhikina T; Riabova O; Lepioshkin A; Grigorov A; Forbak M; Madacki J; Orena BS; Manfredi M; Gosetti F; Buzzi A; Degiacomi G; Sammartino JC; Marengo E; Korduláková J; Riccardi G; Mikušová K; Makarov V; Pasca MR
    ACS Infect Dis; 2020 Feb; 6(2):313-323. PubMed ID: 31729215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high-throughput cidality screen for Mycobacterium tuberculosis.
    Kaur P; Ghosh A; Krishnamurthy RV; Bhattacharjee DG; Achar V; Datta S; Narayanan S; Anbarasu A; Ramaiah S
    PLoS One; 2015; 10(2):e0117577. PubMed ID: 25693161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman RC
    Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzaldehyde thiosemicarbazone derivatives against replicating and nonreplicating Mycobacterium tuberculosis.
    Volynets GP; Tukalo MA; Bdzhola VG; Derkach NM; Gumeniuk MI; Tarnavskiy SS; Starosyla SA; Yarmoluk SM
    J Antibiot (Tokyo); 2019 Apr; 72(4):218-224. PubMed ID: 30662064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against
    Sato MR; Oshiro Junior JA; Machado RT; de Souza PC; Campos DL; Pavan FR; da Silva PB; Chorilli M
    Drug Des Devel Ther; 2017; 11():909-921. PubMed ID: 28356717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.